Smoking Rates Hit Historic Low in US amid Pandemic

Mar.23.2022
Smoking Rates Hit Historic Low in US amid Pandemic
Smoking rates hit an all-time low in the US during the first year of the pandemic, attributed to public health campaigns and lifestyle changes.

According to foreign media reports on March 17, 2022, New York - in the first year of the COVID-19 pandemic, an increasing number of Americans have been abusing alcohol or using illegal drugs, but apparently not smoking.

 

According to survey data released on Thursday by the U.S. Centers for Disease Control and Prevention, smoking rates in the United States have reached a historic low in 2020, with only 1 in 8 adults reporting current use. The CDC also reported a decrease in adult e-cigarette usage.

 

Officials from the Disease Prevention and Control Center attributed this decline to public health campaigns and policies. However, outside experts suggest that increased prices for tobacco products and changes in lifestyle due to epidemics may have also played a role.

 

People who are mainly social smokers no longer have this situation," said Megan Roberts, a researcher at Ohio State University who focuses on tobacco product use among young people and adolescents.

 

More importantly, parents who suddenly had to stay home full-time with their children may have already cut back on expenses. Roberts also added that some individuals may have quit smoking after reports came out suggesting that smokers are more likely to develop severe illnesses if infected with COVID-19.

 

According to a report from the Centers for Disease Control and Prevention, based on a survey of over 31,000 American adults, 19% of Americans used at least one tobacco product in 2020, which is lower than the approximately 21% reported in 2019.

 

The use of cigars, smokeless tobacco, and pipes remain unchanged. Currently, the usage rate of electronic cigarettes has decreased from 4.5% in the previous year to 3.7%.

 

Cigarettes are the most commonly used tobacco product, with 12.5% of adults using them, which is lower than the 14% average.

 

For a long time, public health officials have believed that smoking - a risk factor for lung cancer, heart disease and stroke - is the leading cause of preventable deaths in the United States.

 

In 1965, 42% of American adults were smokers.

 

For several decades, this ratio has been gradually declining for various reasons, including taxes and smoking bans in workplaces and restaurants. However, some experts argue that a significant portion of the recent decline is due to the recent increase in prices.

 

For example, British American Tobacco - a company that produces brands such as Camel, Lucky Strike, and Newport - increased their prices fourfold in 2020, resulting in a total increase of around 50 cents per pack.

 

Interestingly, the amount of cigarettes sold in the United States actually increased in 2020, according to a report from the Federal Trade Commission. This is the first such growth in twenty years.

 

While there may be fewer smokers, those who do smoke tend to smoke more heavily.

 

This is a viable hypothesis - that people have more opportunities to smoke because they are not working," said David Sweanor, the global tobacco policy expert at the University of Ottawa.

 

He said that the investigation by the Disease Prevention and Control Center may also underestimate the number of smokers, either because some interviewees are dishonest or because the investigation missed too many smokers.

 

Other surveys have indicated that alcohol and illegal drug use have increased for many people during the first year of the pandemic.

 

(Source: Associated Press)

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14